Can’t weigh the dual use impact – risk predictions impossible
Yang Xue 1,2, Hanzhi Yu 3,* and Geng Qin 3, 12-20-2021, 1 Law School, Tianjin University, Tianjin 300072, China; 2 Center for Biosafety Research and Strategy, Tianjin University, Tianjin 300072, China 3 School of Public Affairs, Zhejiang University, Hangzhou 310058, China; https://www.mdpi.com/2071-1050/13/24/14056/htm, "Towards Good Governance on Dual-Use Biotechnology for Global Sustainable Development," Sustainability Volume 13 Issue 24 10.3390/su132414056 (ermo/sms, Acc:6-22-2022)
2.2. Predicament 2: Top-Down Public Regulation often Lags behind Technological Iteration Due to Difficulty in the Prediction of Human-Made Risks of Dual-Use Biotechnology
It is difficult to predict the human-made risks of dual-use biotechnology before it has been used. According to Giddens, scientific and technological risk is a kind of “man-made risk” [32], and technology is neither good nor evil in itself. People use technology for good or evil purposes. Compared with the risk of public health and safety, the risk of biotechnological dual-use depends more on the intention and ability of its users. Therefore, the cause of biotechnology dual-use risk is stakeholders’ behavior out of control under the comprehensive influence of both the internal and external environment.
While human beings are innovating dual-use biotechnology, they are endeavoring to modify the rules that should apply to it. However, since the human-made risks of dual-use biotechnology cannot be predicted, since it is easy to find loopholes in rules and policies, and since traditional “hard law” and other governance rules are slow to adjust, governance innovation cannot keep up with technology. The hope is that once governance rules are established, they will be able to keep pace with technological changes by establishing a system of adaptive governance for continuous technology evaluation. With the development of dual-use biotechnology and the deepening understanding of its risks, these methods usually require a cycle of data collection, evaluation and rule modification [33]. In other words, new scientific discoveries and knowledge in other fields must be applied to the iterative decision-making of the dual-use risk of biotechnology [34]. However, such governance innovation ideas tend to challenge the scientific formulation of risk governance.
In summary, the risk of information asymmetry of dual-use biotechnology has placed the traditional biotechnology industry self-governance model in trouble; at the same time, the difficulty of predicting the human-made risks of dual-use biotechnology leads to public regulation lagging behind technical iteration. The result is failed governance of dual-use risks of biotechnology. In the 1920s, Ogburn observed that as technology advanced, people’s habits, thoughts and social arrangements fell behind, resulting in the decisive influence of technology on society [35]. The social reality since World War II has demonstrated that social harmony exists only in the minds of idealists. In contrast, heterogeneity is a basic feature of modern society. On this premise, the predicament of the management of dual-use risk of biotechnology reflects a failure in the checks and balances of the social governance structure. The risk governance rules cannot cover the blind spots of non-state actors and all biotechnology R and D and application scenarios. It is difficult for the system design mechanism to balance and coordinate the viewpoints and propositions in the life sciences and social sciences, in addition to finding a consensus among all parties. The balance between technology iteration and governance rules, and between private subjects’ demands and social consensus is consequently lost.